信隆健康(002105) - 2025 Q2 - 季度业绩预告

Core Performance Forecast The company anticipates a shift from profit to loss in the first half of 2025, with net profit attributable to shareholders projected to be a loss of RMB 9.5 million to RMB 19 million, representing a year-on-year decrease of 245.53% to 391.05% compared to the prior year's profit of RMB 6.528 million Performance Forecast Data | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Year Same Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Loss: RMB 9.5 million – RMB 19 million | Profit: RMB 6.528 million | | Year-on-year Change | Decrease: 245.53% – 391.05% | - | | Net Profit After Non-recurring Gains and Losses | Loss: RMB 14.5 million – RMB 24 million | Profit: RMB 3.8758 million | | Year-on-year Change | Decrease: 474.12% - 719.23% | - | | Basic Earnings Per Share | Loss: RMB 0.026/share – RMB 0.052/share | Profit: RMB 0.018/share | Communication with Accounting Firm The financial data presented in this performance forecast are preliminary estimates by the company and have not been audited by an accounting firm - The financial data related to this performance forecast have not been audited by an accounting firm[4] Analysis of Performance Change The primary reason for the performance decline is market environment changes leading to fluctuations in customer demand, resulting in the company's operating revenue falling short of expectations, which in turn caused a decrease in gross profit, insufficient to cover period expenses, ultimately leading to operating losses - The company's net profit decreased during the reporting period, primarily due to market changes causing fluctuations in customer demand, leading to the company's revenue falling short of expectations, a decline in gross profit, and operating profit being insufficient to cover period expenses, resulting in a loss[5] Other Relevant Explanations and Risk Warning The company emphasizes that this performance forecast is a preliminary estimate by the finance department, and the final data will be subject to the 2025 semi-annual report to be disclosed, advising investors to make cautious decisions and be aware of investment risks - This performance forecast is a preliminary estimate by the company's finance department, unaudited, with specific data subject to the company's disclosed 2025 semi-annual report[6] - The company advises investors to make cautious decisions and be aware of investment risks[8]